Skip to main content
. 2021 Jun 8;4:699. doi: 10.1038/s42003-021-02191-1

Fig. 1. CA-170 is selective for PD-L1, PD-L2, and VISTA among the tested B7 family checkpoint pathways.

Fig. 1

a CA-170 rescued IFNγ release by human PBMCs when stimulated with anti-CD3 and anti-CD28 antibodies, and inhibited by recombinant PD-L1. b CA-170 rescued IFNγ release by human PBMCs when stimulated with anti-CD3 and anti-CD28 antibodies, and inhibited by recombinant VISTA. c CA-170 rescued IFNγ release by human PBMCs when stimulated with anti-CD3 and anti-CD28 antibodies, and inhibited by recombinant PD-L2. d CA-170 did not rescue the release of IL-2 in Jurkat cells stimulated with PHA in the presence of exogenous human B7-1 and inhibited by recombinant hCTLA-4. e CA-170 did not inhibit IL-2 secretion in Jurkat cells stimulated with PHA in the presence of exogenous human B7-1. f Dose response of rescue of IFNγ release by human PBMCs stimulated with anti-CD3 and anti-CD28 antibodies and inhibited by PD-L1 upon treatment with CA-170, anti-PD-1 antibody or isotype control. g Dose response of rescue of IFNγ release by human PBMCs stimulated with anti-CD3 and anti-CD28 antibodies and inhibited by PD-L2 upon treatment with CA-170, anti-PD-1 antibody, or isotype control. h Dose response of rescue of IFNγ release by human PBMCs stimulated with anti-CD3 and anti-CD28 antibodies and inhibited by VISTA upon treatment with CA-170, anti-VISTA antibody, or isotype control. One representative data is presented out of three (ag) or four (h) independent experiments. Each bar/data point in the figures denotes mean ± SD from the three replicates ****p < 0.0001 as calculated by one-way ANOVA (Dunnett’s multiple comparisons test).